What 4 Analyst Ratings Have To Say About TG Therapeutics
Over the past 3 months, 4 analysts have published their opinion on TG Therapeutics (NASDAQ:TGTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
B of A Securities Initiates Coverage On TG Therapeutics with Underperform Rating, Announces Price Target of $5
B of A Securities analyst Alec Stranahan initiates coverage on TG Therapeutics (NASDAQ:TGTX) with a Underperform rating and announces Price Target of $5.
9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics – Read Why
TG Therapeutics Inc’s (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death…
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.